Global Blood Therapeutics's ROA from the second quarter of 2022 to the second quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Global Blood Therapeutics's ROA in the second quarter of 2022?
Global Blood Therapeutics Inc. recorded a cumulative net loss of $-322 million during 12 months ending in the second quarter of 2022, resulting in a negative return on assets (ROA) of -41.58%.

However, within the Healthcare sector 698 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2022 from 4830 to 4854.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter
Y / Y Total Assets Change	45.45 %	37.32 %	32.07 %	-12.57 %	-15.52 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-322	-310	-303	-277	-266
Return On Assets (TTM)	-41.58 %	-43.53 %	-46.26 %	-46.14 %	-42.86 %
GBT's Total Ranking	# 4854	# 4830	# 5198	# 4298	# 4258
Total Assets (TTM) in million	825	823	893	561	567
Seq. Total Assets Change	0.17 %	-7.84 %	59.26 %	-1.07 %	-5.43 %
Seq. Net Income Change	-	-	-	-	-

GBT's 5 Years Annual ROA >> Back to GBT Management Effectiveness >> Compare GBT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 293
Sector	# 699
Overall	# 4739

Return On Assets Statistics
High	Average	Low
-31.1 %	-37.68 %	-48.53 %
(Dec 31 2018)		(Dec 31 2015)

Financial Statements
Global Blood Therapeutics's Assets	$ 825 million	GBT's Balance sheet
Global Blood Therapeutics's Income	$ -82 million	Quarterly GBT's Income Statement
GBT's Income by Division		See GBT's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017
Y / Y Total Assets Change	32.26 %	-15.15 %	28.89 %	73.15 %	76.26 %
Total Assets in million	893	675	796	618	357
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-303	-248	-267	-174	-117
Annual Return On Assets	-33.93 %	-36.65 %	-33.51 %	-28.2 %	-32.81 %

GBT's 5 Years Annual ROA >> Back to GBT Management Effectiveness >> Compare GBT ROA to its Competitors

More Return On Assets Ratios
GBT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GBT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GBT's Competitors
Subscribers only: Roa for Global Blood Therapeutics's Suppliers
Subscribers only: Return On Assets for GBT's Customers

You may also want to know
GBT's Roi	GBT's Inventory Turnover Ratio	GBT's Growth Rates	GBT's Dividend Comparisons
	GBT's Profitability Ratios	GBT's Asset Turnover Ratio	GBT's Dividend Growth
GBT's Roe	GBT's Valuation Ratios	GBT's Financial Strength Ratios	GBT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2022, within Healthcare Sector

ROA

Date modified: 2026-08-30T17:12:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.